Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Steve Foots, CEO of Croda International, has been appointed Commander of the Order of the British Empire (CBE) in the King’s ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

China's biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds ...

This burgeoning market reflects advancements in precision oncology, leveraging neoantigen vaccines tailored to patient-specific tumor mutations. Key growth drivers include next-generation sequencing ...

BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...

Following the closing of the transaction, CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech.